Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Summer-Fall;13(2-3):187-196.
doi: 10.1900/RDS.2016.13.187. Epub 2016 Aug 10.

Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study

Mohsen Janghorbani  1 , Masoud Amini  1 , Ashraf Aminorroaya  1
Affiliations

Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study

Mohsen Janghorbani et al. Rev Diabet Stud. 2016 Summer-Fall.

Abstract

Objectives: To evaluate the ability of low-level fasting high-density lipoprotein cholesterol (HDLC) to predict the incidence of type 2 diabetes (T2D) in an Iranian high-risk population.

Methods: Seven-year follow-up data (n = 1,775) in non-diabetic first-degree relatives (FDR) of consecutive patients with T2D aged 30-70 years were analyzed. The primary outcome was the diagnosis of T2D based on repeated oral glucose tolerance test (OGTT). We used Cox proportional hazard models to estimate the hazard ratio (HR) for the incidence of T2D across quartiles of HDLC, and plotted a receiver operating characteristic (ROC) curve to assess discrimination.

Results: The highest quartile compared with the lowest quartile of HDLC was associated with T2D in age- and gender-adjusted models (HR: 0.83, 95% CI: 0.73-0.95). Further adjustment for fasting plasma glucose and cholesterol attenuated the association for T2D incidence (HR: 0.93, 95% CI: 0.80-1.08). The area under the ROC curve for HDLC was 54.1% (95% CI: 50.2-58.0).

Conclusions: HDLC level was a weak predictor of T2D in an Iranian high-risk population, independent of age and gender.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Kaplan-Meier survival curve
The curve shows the rate of type 2 diabetes incidence for each high-density lipoprotein cholesterol (HDLC) quartile.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves for high-density lipoprotein cholesterol (LDLC), triglyceride (Tg), waist circumference (WC), fasting plasma glucose (FPG), and systolic blood pressure (BP) to predict type 2 diabetes in first-degree relatives of patients with type 2 diabetes. Estimates of the area under the ROC curves and their 95% confidence intervals are shown in the table.
See this image and copyright information in PMC

References

    1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton GD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15. - PubMed
    1. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893–2898. - PubMed
    1. Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk factor in heart failure. Int Heart J. 2009;50:571–580. - PubMed
    1. Rahilly-Tierney CR, Spiro A 3rd, Vokonas P, Gaziano JM. Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study) Am J Cardiol. 2011;107:1173–1177. - PubMed
    1. Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus GA, Dada M, Chaitman BR, Mancini GB, Weintraub WS. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol. 2013;62:1826–1833. - PMC - PubMed

LinkOut - more resources